Pediatrix Medical Group, Inc. $MD Shares Purchased by Hillsdale Investment Management Inc.

Posted by Jeff Wilder on Feb 21st, 2026

Hillsdale Investment Management Inc. raised its holdings in Pediatrix Medical Group, Inc. (NYSE:MD – Free Report) by 20.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 452,200 shares of the company’s stock after buying an additional 75,700 shares during the period. Hillsdale Investment Management Inc.’s holdings in Pediatrix Medical Group were worth $7,574,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Allianz Asset Management GmbH boosted its stake in Pediatrix Medical Group by 159.1% in the second quarter. Allianz Asset Management GmbH now owns 61,412 shares of the company’s stock valued at $881,000 after acquiring an additional 37,712 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of Pediatrix Medical Group in the 3rd quarter valued at about $513,000. Hsbc Holdings PLC boosted its position in shares of Pediatrix Medical Group by 226.6% in the 2nd quarter. Hsbc Holdings PLC now owns 111,997 shares of the company’s stock valued at $1,591,000 after purchasing an additional 77,704 shares during the period. Edgestream Partners L.P. purchased a new position in Pediatrix Medical Group during the 2nd quarter worth approximately $763,000. Finally, Wedge Capital Management L L P NC purchased a new position in Pediatrix Medical Group during the 3rd quarter worth approximately $2,315,000. 97.71% of the stock is owned by institutional investors and hedge funds.

Pediatrix Medical Group Stock Performance

NYSE:MD opened at $18.80 on Friday. The firm’s fifty day moving average price is $21.56 and its 200 day moving average price is $19.56. Pediatrix Medical Group, Inc. has a 1-year low of $11.84 and a 1-year high of $24.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.82 and a quick ratio of 1.83. The firm has a market cap of $1.61 billion, a price-to-earnings ratio of 9.69 and a beta of 0.76.

Pediatrix Medical Group (NYSE:MD – Get Free Report) last announced its quarterly earnings data on Thursday, February 19th. The company reported $0.50 EPS for the quarter, missing analysts’ consensus estimates of $0.53 by ($0.03). Pediatrix Medical Group had a return on equity of 19.59% and a net margin of 8.64%.The firm had revenue of $493.77 million for the quarter, compared to analysts’ expectations of $486.23 million. During the same quarter in the previous year, the company posted $0.51 EPS. The firm’s quarterly revenue was down 1.7% compared to the same quarter last year. On average, sell-side analysts expect that Pediatrix Medical Group, Inc. will post 1.38 EPS for the current year.

Key Stories Impacting Pediatrix Medical Group

Here are the key news stories impacting Pediatrix Medical Group this week:

Positive Sentiment: Management flagged declining costs and a stronger 2026 EBITDA outlook, which could support margin expansion and earnings recovery. Pediatrix Medical Q4 Earnings Miss Estimates Despite Declining Costs
Positive Sentiment: Revenue topped consensus and same-unit gains plus resilient pricing and payer mix offset volume weakness, indicating underlying operational resilience. Pediatrix Medical Group’s (NYSE:MD) Q4 CY2025 beats on revenue
Neutral Sentiment: Earnings call and full transcripts are available for review — useful for investors who want detail on patient volumes, payer trends and timing of margin benefits. Pediatrix Medical Group, Inc. (MD) Q4 2025 Earnings Call Transcript
Neutral Sentiment: Analyst coverage and call highlights emphasize a steady margin focus — this is constructive but depends on execution and volume recovery. Pediatrix Medical Earnings Call Highlights Steady Margin Focus
Negative Sentiment: EPS missed consensus (by $0.03) and EPS declined vs. prior year, which pressured near-term sentiment and prompted the intraday sell-off. Pediatrix Medical Group (MD) Q4 Earnings Lag Estimates
Negative Sentiment: Patient volume weakness led to a 1.7% YoY revenue decline despite pricing gains — recovery in volumes will be critical for sustained earnings upside. MD Q4 deep dive: Pricing and payer mix resilience offset volume weakness

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. UBS Group boosted their price objective on Pediatrix Medical Group from $16.50 to $23.00 and gave the company a “neutral” rating in a research note on Wednesday, November 5th. Zacks Research cut shares of Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a report on Friday, January 23rd. Truist Financial reduced their price target on shares of Pediatrix Medical Group from $24.00 to $21.00 and set a “hold” rating for the company in a research report on Thursday. Deutsche Bank Aktiengesellschaft set a $19.00 price target on shares of Pediatrix Medical Group in a research note on Friday. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Pediatrix Medical Group in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, Pediatrix Medical Group presently has an average rating of “Hold” and an average target price of $20.00.

Check Out Our Latest Research Report on Pediatrix Medical Group

Insider Activity

In related news, CEO Mark S. Ordan sold 23,000 shares of the stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $22.41, for a total transaction of $515,430.00. Following the completion of the transaction, the chief executive officer directly owned 302,805 shares of the company’s stock, valued at $6,785,860.05. This represents a 7.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.90% of the stock is currently owned by company insiders.

About Pediatrix Medical Group

(Free Report)

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.